retatrutide type 2 diabetes phase 2 trial results 2024 Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a clinical There are many great research – Retatrutide Phase 2: Type 2

In the Phase 3 trials, adults taking retatrutide 12mg lost an average of 28.7% of their body weight after 68 weeks

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements

Published research of our programme in JMIR Formative Research reports an average weight loss of 19.1% at 12 months with semaglutide and behavioural support

Learn more about these GLP-1 medication changes in 2025

CagriSema vs Retatrutide is one of the most important next-generation obesity peptide comparisons going into 2026

For longer trips, gradually shift your injection time by one to two hours each week leading up to and during travel